Kuros Biosciences (KURN) AI Stock Analysis

• Market Cap: CHF1.12B
• Dividend Yield: N/A
• Average Volume (3M): 144.47K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: 104.01%
• EPS Growth: 33.25%
• Country: CH
• Employees: 122
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 39,154,606
• 10 Day Avg. Volume: 104,733
• 30 Day Avg. Volume: 144,472
• PEG Ratio: 2.90
• Price to Book (P/B): 13.52
• Price to Sales (P/S): 10.51
• P/FCF Ratio: 391.61
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF36.50
• Price Target Upside: 29.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: CHF32.00 ▲(13.64% Upside)

The overall stock score of 61 reflects strong financial performance with revenue growth and a solid balance sheet, but is tempered by negative profit margins and valuation concerns due to ongoing losses. Technical indicators show positive momentum, but caution is advised as the stock approaches overbought levels.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, enhancing long-term business sustainability and competitiveness.

Cash Flow Improvement

Positive cash flow from operations suggests better cash management and financial health, providing more resources for reinvestment and growth.

Balance Sheet Strength

A strong balance sheet with low leverage enhances financial stability, providing resilience against economic fluctuations and supporting long-term growth.

Negative Factors

Profitability Challenges

Ongoing profitability issues can hinder reinvestment and growth, posing risks to long-term financial sustainability and investor confidence.

Negative Net Profit Margin

A negative net profit margin reflects operational inefficiencies, which may limit the company's ability to generate sustainable profits in the future.

Negative Return on Equity

Negative return on equity indicates that the company is not generating sufficient returns on shareholder investments, potentially impacting investor sentiment.

Kuros Biosciences Business Overview & Revenue Model

Company Description

Kuros Biosciences (KURN) is a biotechnology company focused on developing advanced biomaterials for regenerative medicine and bone healing. The company operates primarily in the medical technology sector, specializing in the development of innovative products that enhance the healing process of bone and soft tissue injuries. Kuros's core products include its proprietary bone grafts and related technologies designed to improve patient outcomes in orthopedic and dental applications.

How the Company Makes Money

Kuros Biosciences generates revenue primarily through the sale of its biomaterial products, including bone graft substitutes and related medical devices. The company's revenue model is built on direct sales to hospitals, clinics, and surgical centers, as well as partnerships with larger medical device companies for distribution. Additionally, Kuros may engage in collaborative research agreements or licensing deals that provide upfront payments and royalties based on future sales of their products. The company's strategic focus on innovation and clinical efficacy, coupled with regulatory approvals from health authorities, further bolsters its market position and contributes to its earnings.

Kuros Biosciences Financial Statement Overview

Summary

Kuros Biosciences shows strong revenue growth and improved cash flows, but profitability remains a challenge with negative profit margins and return on equity. The balance sheet is robust with low debt, providing financial stability.

Income Statement

The company has demonstrated strong revenue growth with a remarkable increase from CHF 33.56 million in 2023 to CHF 75.55 million in 2024. The gross profit margin is healthy at 82.09%. However, the net profit margin remains negative at -4.92%, indicating the company is still incurring losses. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows strength with a significant equity base, as indicated by the equity ratio of 69.46%. The debt-to-equity ratio is low at 0.03, suggesting minimal leverage. The return on equity remains negative at -6.32%, reflecting the company's current unprofitability.

Cash Flow

Cash flow from operations has improved significantly, turning positive in 2024 to CHF 3.14 million. The free cash flow also shows a positive trend, indicating better cash management. The free cash flow to net income ratio is positive, suggesting efficient cash conversion despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	107.19M	75.56M	33.56M	17.99M	13.81M	4.04M
Gross Profit	94.89M	62.03M	23.94M	10.77M	10.07M	1.67M
EBITDA	2.13M	-561.00K	-6.84M	-8.84M	-5.29M	-8.58M
Net Income	-6.09M	-3.72M	-13.73M	-14.60M	-7.54M	-11.52M
Balance Sheet
Total Assets	109.97M	84.54M	71.46M	82.95M	91.34M	94.36M
Cash, Cash Equivalents and Short-Term Investments	17.90M	17.46M	14.21M	24.07M	28.62M	28.39M
Total Debt	1.79M	1.79M	2.14M	1.91M	8.93M	2.34M
Total Liabilities	33.32M	25.79M	14.75M	14.09M	14.36M	9.76M
Stockholders Equity	76.65M	58.75M	56.71M	68.86M	76.98M	84.60M
Cash Flow
Free Cash Flow	-787.00K	2.03M	-9.17M	-7.75M	-5.83M	-9.46M
Operating Cash Flow	779.00K	3.14M	-8.84M	-7.35M	-5.45M	-9.24M
Investing Cash Flow	-1.57M	-1.11M	-326.00K	-400.00K	-374.00K	-220.00K
Financing Cash Flow	1.65M	1.34M	-171.00K	3.22M	6.08M	17.08M

Kuros Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 28.16
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:KURN, the sentiment is Neutral. The current price of 28.16 is below the 20-day moving average (MA) of 29.45, below the 50-day MA of 29.51, and above the 200-day MA of 25.71, indicating a neutral trend. The MACD of 0.39 indicates Positive momentum. The RSI at 44.82 is Neutral, neither overbought nor oversold. The STOCH value of 19.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CH:KURN.

Kuros Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NWRN	74 Outperform	CHF402.21M	16.82	―	―	744.64%	―
BSLN	73 Outperform	CHF568.22M	7.80	―	―	58.51%	―
KURN	61 Neutral	CHF1.12B	―	-7.82%	―	104.01%	33.25%
MOLN	54 Neutral	$129.20M	-1.97	-49.86%	―	-100.00%	14.45%
SANN	53 Neutral	$163.05M	-2.38	-301.13%	―	-56.85%	-186.55%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IDIA	44 Neutral	CHF890.38M	-5.36	―	―	229.23%	63.47%

Kuros Biosciences Corporate Events

Kuros Biosciences Reports Strong Revenue Growth and Strategic Expansion

Kuros Biosciences announced a 77% year-over-year increase in revenue for the first nine months of 2025, driven by strong sales of its MagnetOs products. The company has launched the MagnetOs MIS Delivery System in the U.S., following FDA clearance, and received approval for MagnetOs products in Saudi Arabia, marking significant milestones in its strategic expansion and positioning in the medical device industry.

Kuros Biosciences Investigates Allegations Against Former Board Member

Kuros Biosciences is addressing media inquiries regarding the resignation of former Board member Albert Arp, who allegedly shared price-sensitive information with an unrelated third party. The company is conducting an internal investigation but assures that this issue does not affect its strategic direction, financial results, or operations.